about
Amino acids for amyotrophic lateral sclerosis / motor neuron diseaseAmino acids for amyotrophic lateral sclerosis / motor neuron diseaseWhole-genome analysis of sporadic amyotrophic lateral sclerosisClinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosisPotential Environmental Factors in Amyotrophic Lateral SclerosisNovel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosisAmyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryPhase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.Amyotrophic lateral sclerosis and neurosarcoidosis: a case report.How common is depression among ALS caregivers? A longitudinal studyNecroptosis drives motor neuron death in models of both sporadic and familial ALS.Senataxin mutations and amyotrophic lateral sclerosis.Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trialBioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients.A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis: objective upper motor neuron markers.Drug therapy in amyotrophic lateral sclerosis.Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.Differential susceptibility of the ocular motor system to disease.Recent advances in amyotrophic lateral sclerosis research.Oxidative stress biomarkers in sporadic ALSA novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALSAmyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron.Depression and wish to die in a multicenter cohort of ALS patients.Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.Randomized control trials in ALS: lessons learned.Controversies and priorities in amyotrophic lateral sclerosis.Primary Lateral SclerosisPromoting excellence in end-of-life care in ALS.Why people play: artificial lives acquiring play instinct to stabilize productivity.Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD)Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional PopulationPhenotypic and molecular analyses of primary lateral sclerosis.Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.Clinical care of patients with amyotrophic lateral sclerosis.
P50
Q24243319-473E93CA-EA96-4F87-9000-BC80851551EFQ24247715-50D2BCAF-27EE-4F2E-9B31-2B7EE0EF6546Q24329076-4B80A2E3-5324-4EAC-BDE9-94E1D0BE5978Q28392768-729A8861-7E4E-4D09-A9B7-E8D2A50CDFA2Q28393938-85FCA6AF-7452-4EF7-8961-36FFE8ED81FBQ28473603-350D5DAB-18CB-4E45-92E5-FB18B68BF95AQ30444138-C0D1D829-1D03-48B9-90E9-80B57E03FDA5Q30494108-F562CC7E-A78D-4C8F-B85D-65D7723A4975Q30579321-A462D0F3-C1B3-4A25-8240-1180042DEAF2Q30580436-0FDC0191-35F0-41CB-B642-389289F6C164Q30619235-F2FD9DE0-9927-4DE2-9005-E0076FF57D8EQ30728028-7BE5D435-9A04-4A20-9EC9-EBD82DC326BEQ33761054-5C7635DA-1AE2-419D-AEDC-390DE52DCA06Q33925475-7164D045-F03F-4107-97BC-A07F69C471E4Q34039826-B6E19FF8-1CE6-4C5B-A149-B77B00057C83Q34156857-7570754E-84D0-4DD0-B132-DDE85C46890AQ34251334-82A54025-27A2-4D64-B54F-F13FC8DE4098Q34315397-9CF639B4-F2CF-4421-84C0-F82BA6AC98CCQ34352883-9AC4E342-D5AC-43B6-900E-C0C495E2B03BQ34566679-78A90A1C-7BE6-4B57-B1DC-44BEA434C2D3Q34573598-DA6E0C4F-43B1-4669-85FE-AD21F29DC1D6Q34584573-939FF27C-19DC-4CF1-9E79-F2E6D2D3ECC1Q34605655-00F6A799-B5AC-4547-863E-BCD412453A4AQ35036503-220A1F4C-8CAF-4D69-9947-1AF8AB7C1C58Q35094635-02400329-7F10-44C1-9368-74A0CD957132Q35162749-9B691417-9002-4A42-AB68-861342F2C6CBQ35214943-E1912A18-4D83-43D9-BF03-56FB21843B7BQ35293000-42D26634-708C-488A-A885-F362FF9DDB10Q35638940-D82DD896-D5DF-49C8-B50D-F0A5010D3221Q35809317-055CCD00-A96F-4315-8CF6-DA6968E89600Q35932089-30B1B7D1-CD08-40F0-A6FC-81E8288D5D64Q36045826-D1DBEE74-1E2F-43D8-A78C-ED0F3CCAA758Q36236426-AF19B3DF-D636-415A-8182-D5555729D403Q36267647-0109002D-EEE3-4E48-B13E-D9CC41AB5600Q36457928-A38C9E2E-14BE-4C92-A705-450A1EEDEBCBQ36484548-96121915-E5AA-4DD7-9F44-6AC9D18D32CFQ36629768-5FA0D9E4-8A91-48C8-88E0-C15834679F8AQ36766094-165C84CC-D8A3-4256-B563-88BE8B2B8600Q36796484-5B563F8D-4198-4572-BA7A-8BBA8B12DC9EQ36947727-B06A0C60-C0E0-48E1-84F8-906CF06E0B94
P50
description
researcher
@en
wetenschapper
@nl
name
Hiroshi Mitsumoto
@en
Hiroshi Mitsumoto
@nl
type
label
Hiroshi Mitsumoto
@en
Hiroshi Mitsumoto
@nl
prefLabel
Hiroshi Mitsumoto
@en
Hiroshi Mitsumoto
@nl
P31
P496
0000-0001-6259-8923